If you were not able to attend the workshop on 4 October 2017, “What’s New in the Treatment of Waldenstrom’s Macroglobulinemia (WM),” it is available online via webcast here (link is external) or on telephone replay… Continue reading →
As someone living with an “indolent” cancer (slow to develop, treatable, but so-far incurable) for the last dozen years, I have decided that the best way for me to think of it is as a hobby. It is fascinating, time-consuming and… Continue reading →
BGB-3111 is a potent and highly selective small molecule BTK inhibitor (Bruton’s Tyrosine Kinase), which we are developing as a monotherapy and in combination with other therapies for the treatment of a variety of lymphomas—the most common form of blood… Continue reading →
Judith Trotman, MD, clinical associate professor, medicine, Concord Clinical School, The University of Sydney, discusses results of a trial investigating BGB-3111 in patients with Waldenstrom’s macroglobulinemia (WM).